Skip to main content
S&P 5007,623.68-0.52%DOW52,215.16-1.23%NASDAQ25,955.34-0.21%BTC$80,645.00-0.98%ETH$2,373.55-0.82%GOLD$4,010.00-1.24%OIL$103.44+3.99%
Smart Investors Daily
SID Premium
Ligand Pharmaceuticals, Inc. logo

OTC · LGNXZ

Ligand Pharmaceuticals, Inc.

Healthcare · Medical - Pharmaceuticals

$0.00

Up+$0.00 (+50.00%)

Updated Oct 26, 2026, 5:59 AM

SID Score

4.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
23.62K
P/E ratio
99
Dividend yield
0.00%
52-week range
— – —
Volume
500
Avg. volume
62.65K

Price performance · LGNXZ

LGNXZ price history

1M range · 0 trading sessions · Daily adjusted prices

LGNXZ does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest LGNXZ news

The latest Smart Investors Daily articles mentioning LGNXZ.

Stock researchCompany · Overview

LGNXZ research

Overview

Company profile and research snapshot.

Company profile

LIGAND PHARMS GLUCAGON

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
—
Implied upside
—
Analysts
13
LGNXZ recent ratings
DateFirmRatingTarget
Sep 25, 2026BarclaysOverweight—
Sep 24, 2026HC Wainwright & Co.Buy—
Sep 23, 2026CitigroupBuy—
Aug 14, 2026Leerink PartnersOutperform—
Aug 7, 2026RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

Ligand to Host Investor Day on December 8, 2026

JUPITER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place on Tuesday, December 8, 2026 from 10:30 a.m. to 12:00 p.m. ET at the Harvard Club of New York City at 35 West 44th Street, New York, NY 10036. The event will include presentations from Ligand CEO Todd Davis, CFO Tavo Espinoza and other members of the Ligand senior management team. Presentations will highlight the company’s strategy, inve

Yahoo · Oct 15, 2026

Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026

JUPITER, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2026 financial results on Thursday, October 29, 2026. The company will hold a conference call beginning at 8:30 a.m. Eastern time to discuss the results and provide a general business update. Conference Call and Webcast Information Date:Thursday, October 29, 2026 Time:8:30 a.m. Eastern time Conference Call:United States (Local): +1 (585) 542-9983 U

Yahoo · Sep 27, 2026

Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is building a business model that differs from that of many drug developers. Rather than relying on internally operated drug development programs, the company funds third-party programs and acquires royalty interests in exchange for economic rights in those assets. That model allows it to generate royalties and other income when the […]

Yahoo · Jul 16, 2026

Ligand Pharmaceuticals (LGND) Stock Looks Undervalued On Cash Flow Yet Overvalued On Earnings

Ligand Pharmaceuticals stock has delivered a very large 338.7% return over the past three years, yet its valuation signals are split, with an intrinsic value estimate from a Discounted Cash Flow (DCF) model suggesting the shares trade below that estimate while market multiples and a low overall value score point to a richer pricing. The 338.7% three year return puts a spotlight on whether the current price already embeds much of the good news in Ligand Pharmaceuticals. The completed US$739m...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By